日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Safety and efficacy of Cisplatin in combination with Sintilimab and Niraparib in patients with advanced solid tumors: A phase Ib study

顺铂联合信迪利单抗和尼拉帕利治疗晚期实体瘤患者的安全性和有效性：一项 Ib 期研究

期刊:Cancer Pathogenesis and Therapy
影响因子:2.8
doi:10.1016/j.cpt.2025.08.005
Tao, Haitao; Liu, Yining; Wang, Lijie; Wang, Jinliang; Ma, Junxun; Zhang, Guoqing; Liu, Zhefeng; Hu, Yi
发表日期：2026
文献求助 收藏

Integrating genomic and pathological characteristics to enhance prognostic precision in advanced NSCLC

整合基因组和病理特征以提高晚期非小细胞肺癌的预后准确性

期刊:npj Precision Oncology
影响因子:8
doi:10.1038/s41698-025-01056-8
Han, Yingjie; Ma, Junxun; Liu, Zhefeng; Wang, Lijie; Zhang, Fan; Huang, Di; Liu, Siyao; Hu, Jifang; Xiao, Wenhua; Wang, Hong; Wen, Juyi; Qin, Haifeng; Gao, Hongjun; Li, Xiaosong; Huang, Ziwei; Zhang, Jiali; Zhang, Yue; Sun, Dawei; Su, Junyan; Chen, Jing; Niu, Beifang; Tao, Haitao; Yang, Bo; Liu, Xiaoqing; Wang, Jinliang; Hu, Yi
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC: a single-arm phase II study

HDAC抑制剂联合替雷利珠单抗和化疗一线治疗晚期非小细胞肺癌：一项单臂II期研究

期刊:Oncologist
影响因子:4.2
doi:10.1093/oncolo/oyaf155
Wang, Lijie; Gao, Ming; Wang, Ting; Cui, Pengfei; Chen, Guangying; Han, Xiao; Ma, Zhiqiang; Yang, Wenyu; Jing, Fangfang; Ma, Junxun; Zhang, Fan; Tao, Haitao; Hu, Yi
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial

卡瑞利珠单抗联合法米替尼治疗既往接受过治疗的非小细胞肺癌患者的疗效和安全性：一项单臂 II 期试验

期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/17588359241311058
Gao, Ming; Zhang, Xia; Yan, Huan; Zhao, Yan; Yuan, Fang; Sun, Decong; Yang, Xuejiao; Ju, Yanfang; Wang, Lijie; Tao, Haitao; Tian, Luyuan; Zhao, Changhong; Ma, Junxun; Hu, Yi; Liu, Zhefeng
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Treatment strategies with combined agency against severe viral pneumonia in patients with advanced cancer

针对晚期癌症患者严重病毒性肺炎的联合治疗策略

期刊:Journal of Translational Internal Medicine
影响因子:7.4
doi:10.2478/jtim-2024-0007
Zhang, Fan; Li, Tao; Bai, Yibing; Liu, Jiayi; Qin, Jiapei; Wang, An; Zhu, Yimin; Zhang, Min; Ma, Zhiqiang; Zhou, Xin; Wang, Lijie; Gao, Ming; Wu, Xiaodong; Shao, Yan; Zhao, Xiangfei; Wen, Juyi; Guan, Jingzhi; Wang, Jinliang; Ma, Junxun; Tao, Haitao; Hu, Yi
肺炎
肿瘤
肿瘤免疫
微生物学
毒理研究
发表日期：2024
文献求助 收藏

Gut mycobiome as a potential non-invasive tool in early detection of lung adenocarcinoma: a cross-sectional study

肠道真菌群作为肺腺癌早期检测的潜在非侵入性工具：一项横断面研究

期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-023-03095-z
Liu, Qingyan; Zhang, Weidong; Pei, Yanbin; Tao, Haitao; Ma, Junxun; Li, Rong; Zhang, Fan; Wang, Lijie; Shen, Leilei; Liu, Yang; Jia, Xiaodong; Hu, Yi
微生物学
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Programmed Cell Death Protein 1 Inhibitor-Mediated Peripheral Neuropathy

程序性细胞死亡蛋白1抑制剂介导的周围神经病变

期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2023.100495
Ao, Yanyun; Gao, Ming; Sun, Binbin; Hao, Hongjun; Yan, Huan; Li, Chuntong; Sun, Decong; Yang, Xuejiao; Ju, Yanfang; Zhang, Xia; Ma, Junxun
细胞生物学
发表日期：2023
文献求助 收藏

Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis

PD-1抑制剂与PD-L1抑制剂联合铂类-依托泊苷一线治疗广泛期小细胞肺癌的疗效和安全性比较：一项多中心真实世界分析

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-023-11709-1
Wang, Yanrong; Li, Lingling; Hu, Jia; Zhao, Yan; Yan, Huan; Gao, Ming; Yang, Xuejiao; Zhang, Xia; Ma, Junxun; Dai, Guanghai
肺癌
肿瘤
肿瘤免疫
PD-L1
细胞生物学
PD-1
发表日期：2023
文献求助 收藏

Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer

RET融合阳性非小细胞肺癌患者发生普拉替尼相关性肺炎

期刊:Supportive Care in Cancer
影响因子:3
doi:10.1007/s00520-023-08125-3
Gao, Ming; Zhang, Xia; Yan, Huan; Sun, Decong; Yang, Xuejiao; Yuan, Fang; Ju, Yanfang; Wang, Lijie; Wang, Jinliang; Zhao, Wei; Zhang, Dong; Li, Lin; Xu, Xiaoyun; Ma, Junxun; Hu, Yi; Zhang, Xiaotao
肺炎
肺癌
肿瘤
RET
肿瘤免疫
细胞生物学
发表日期：2023
文献求助 收藏

Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors

中性粒细胞与淋巴细胞比值基线及变化对接受PD-1抑制剂治疗的体能状态较差的晚期非小细胞肺癌患者生存期的预后价值

期刊:Translational Lung Cancer Research
影响因子:3.5
doi:10.21037/tlcr-21-43
Chen, Shixue; Li, Ruixin; Zhang, Zhibo; Huang, Ziwei; Cui, Pengfei; Jia, Wangping; Zhang, Sujie; Tao, Haitao; Wang, Lijie; Li, Xiaoyan; Wang, Jinliang; Ma, Junxun; Liu, Zhefeng; Huang, Di; Zheng, Xuan; Saito, Yuichi; Ichiki, Yoshinobu; Hu, Yi
肺癌
肿瘤
中性粒细胞
肿瘤免疫
粒细胞
细胞生物学
PD-1
发表日期：2021
文献求助 收藏